ABSTRACT
Objective To investigate the clinical features,diagnosis,treatment and prognosis of the renal secondary tumor.Methods From January 2000 to January 2014,the data from 31 patients,including 23 male patients and 8 female patients,with renal secondary tumors were analyzed retrospectively.Their mean age was 56 years old (ranging from 38 to 75 years old).The 31 renal secondary tumors rooted in lung cancer(n =14),lymphoma(n =5),colorectal cancer and gastric cancer(n =3),breast cancer(n =2),esophageal cancer(n =1),thyroid cancer (n =1),cervical cancer (n =1) and bladder cancer (n =1),respectively.There were 22 patients (71.0％) of renal metastasis accompany with other organs or lymph node metastasis.9 cases (29％) suffered with independent renal metastasis and 21 cases (67.7％) suffered with unilateral renal metastasis.5 cases(16.1％) were diagnosed as primary tumor with the renal metastasis at the same time,and the remaining 26 cases were found renal metastasis within 9 to 72 months after primary tumor (mean 30 months).There were only 5 patients (16.1％) with symptom.Ultrasound showed low echo range in 20 cases (65.6％) or uneven echo in 11 cases (34.4％).CT showed equal density (77.4％) in 24 cases or slightly low density shadow (22.6％) in 7 cases,most of which were endogenous,mild enhancement.10 cases (32.3％) were bilateral renal metastasis,unilateral renal multiple metastases was found in 6 cases (19.4％),and single metastasis was noticed in 15 cases (48.4％).The average diameter of the renal metastasis was 2.7 cm (ranging from 0.9 to 6.8 cm).Except 4 cases gave up the treatment,the remaining 27 cases were accepted comprehensive therapy about the primary tumor.the 9 patients with renal metastasis only were treated with chemotherapy or targeted therapy for the advanced primary tumor.Among the 9 patients,6 cases were undergone NSS or radical nephrectomy (RN) treatment.Results In 9 cases with only renal metastasis,6 cases,treated by surgery,recovered well.Postoperative pathological and immunohistochemical results confirmed the renal metastasis.Up to January 2015,the follow-up duration ranged from 2 months to 60 months [mean (22.6 ± 18.4) months].The survival time ranged from 1 month to 51 months [mean (13.2 ± 13.2) months].Among 22 cases with multiple metastasis,4 cases gave up treatment,whose average survival time was (2.0 ± 1.4) months.However,the average survival time in remaining 18 cases was (11.1 ± 4.7) months (P ＜ 0.05).In 9 cases with independent renal metastasis,the average survival time in 6 cases,accepted the procedure,was (26.2 ± 18.6) months.While,the average survival time in remaining 3 non-surgical cases,was (10.3 ± 4.0) months (P ＜ 0.05).Conclusions Renal secondary tumor was rare in clinic.Most cases have isolated lesion.Renal secondary tumor was advanced manifestation of the primary tumor,which could prolong the survival time according to the comprehensive treatment for the primary tumor.Surgical resection of the lesion before the comprehensive treatment could be chosen in the independent renal metastasis.
ABSTRACT
Objective To investigate the diagnosis value of mucin 7 in plasma and urine in the detection of bladder cancer.Methods Expression of mucin 7 was detected quantitatively in plasma and urine from 23 patients with bladder cancer and 23 patients as control group by enzyme-linked immunosorbent assay(ELISA) from November 2012 to September 2013.There were 15 were male and 8 were female in the 23 bladder cancer patients,aged from 41 to 95 years,with an average of 64 years.Of the 23 bladder cancer pathology,12 with high grade,11 with low grade,11 with invasive disease and 12 with noninvasive disease.There were 19 males and 4 females in the 23 patients in control group,aged from 28 to 85 years,with an average of 61 years.Results The amount of mucin 7 in plasma was significantly higher in bladder cancer group than that in control group [(7.43±4.54) ng/ml versus (4.55±.1.98) ng/ml,P=0.017].While there was no significant difference in urine between the two groups [(12.44±7.1 1) ng/ml versus (11.96±8.41)ng/ml,P=0.840].There was no significant differences in the amount of mucin 7 had in different grades and stages of bladder cancer (P＞0.05).Conclusions Expression of mucin 7 in plasma of patients with bladder cancer is significantly higher than that in control group.Mucin 7 expression has no significant correlation with the grading and staging of bladder cancer.Detecting mucin 7 expression quantitatively with ELISA for diagnosis of bladder cancer is a method with certain value.
ABSTRACT
Objective To assess the effectiveness and safety of vitamin D in preventing and treating bone loss in renal transplant patients.Methods Methods recommended by the Cochrane Collaboration were used.MEDLINE,EMBase,Cochrane Library and CNKI were searched from Jan.1990 to Nov.2009 to locate all the randomized controlled trials (RCT) concerning preventing and treating bone loss by vitamin D in renal transplant patients.The qualities of included trials were evaluated by two independent reviewers.Trails consistent with criteria wereanalyzed by Revman 4.2 software.Results Nine RCTs involving 658 post transplant patients were included.The qualities of included trials were graded as grade A in 4,grade B in 2 and grade C in 3.Meta-analysis showed that after being treated with vitamin D for one year,the difference of BMD,Z-score and T-score between the two groups was statistically significant (P＜ 0.05); the difference of PTH concentration was also statistically significant (P＜0.01),but there was no significant difference in concentrations of serum calcium and phosphorus,and the incidence of hypercalcemia (P＞0.05).Conclusion Current available evidence demonstrates that vitamin D is effective and safe in preventing and treating bone loss in renal transplant patients.